Protalix's PRX-115 keeps uric acid below target for up to 12 weeks in Phase 1 study
PLX•Protalix BioTherapeutics said Phase 1 results showed higher PRX-115 doses sustained uric acid lowering longer, keeping it below target for up to 12 weeks. The company said the treatment was generally well tolerated and Phase 2 top-line results are expected in the second half of 2027.
1. Study results and next steps
Protalix BioTherapeutics said higher PRX-115 doses sustained uric acid lowering longer in a Phase 1 study, supporting less frequent dosing for uncontrolled gout; the findings will be presented at ACR Convergence on November 10, 2026. Treatment was generally well tolerated, with one anaphylactic reaction that resolved and no other serious adverse events reported; the Phase 2 RELEASE trial is testing dosing every four weeks without methotrexate or every eight weeks with methotrexate, with top-line results expected in the second half of 2027.
